Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis

V. Kowdley, Kris; C. Gordon, Stuart; Rajender Reddy, K.; Rossaro, Lorenzo; Bernstein, David; Lawitz, Eric; L. Shiffman, Mitchell; R. Schiff, Eugene; Ghalib, Reem; J. Ryan, Michael; K. Rustgi, Vinod; Chojkier, Mario; Herring, Robert; M. Di Bisceglie, Adrian; J. Pockros, Paul; Mani Subramanian, G.; An, Di; S. Svarovskaia, Evguenia; H. Hyland, Robert; S. Pang, Phillip; T. Symonds, William; G. McHutchison, John; J. Muir, Andrew; Pound, David; Fried, Michael

doi:10.1056/nejmoa1402355

Public

Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis

Published in New England Journal of Medicine • Apr 11, 2014

Authors:

Kris V. Kowdley

Stuart C. Gordon

K. Rajender Reddy

Abstract

BACKGROUND: High rates of sustained virologic response were observed among patients with hepatitis C virus (HCV) infection who received 12 weeks of treatment with the nucleotide polymerase inhibitor sofosbuvir combined with the NS5A inhibitor ledipasvir. This study examined 8 weeks of treatment with...

Subject

Medicine

Sofosbuvir

Ledipasvir

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!